Skip to content

Study · Randomized controlled trial · 2021

4 results

Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.

Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D

The Journal of clinical endocrinology and metabolism1 Sept 2021Cited by 74 (Europe PMC)

PMID34097062 (opens in a new tab)DOI10.1210/clinem/dgab408 (opens in a new tab)PepBankPUB-34097062
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese women with PCOS, exenatide alone significantly improved mean glucose, insulin sensitivity and insulin secretion.

    In plain wordsIn obese women with PCOS, exenatide alone improved mean blood sugar, insulin sensitivity and insulin secretion from baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedMean glucose, insulin sensitivity and secretion
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg weekly · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Despite equivalent reductions in BMI and WC with PHEN/TPM, only EQW/DAPA and EQW resulted in significant improvements in MBG, SI, and IS.
    1 context sentence
    Summary · context
    Nondiabetic women (n = 119; aged 18-45 years) with a body mass index (BMI) greater than 30 and less than 45 and polycystic ovary syndrome (National Institutes of Health criteria)

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In obese women with PCOS, exenatide plus dapagliflozin and phentermine/topiramate produced the greatest reductions in weight, total fat and waist circumference.

    In plain wordsIn obese women with PCOS, exenatide plus dapagliflozin and phentermine/topiramate produced the largest combined reductions in weight, fat and waist size.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight, total body fat and waist circumference
    Study

    n: not reported in source

    Comparator
    Other trial regimens
    Outcome group
    Body composition · Metabolic and weight

    Source sentences

    Summary
    EQW/DAPA and PHEN/TPM resulted in the most loss of weight and total body fat by DXA, and WC.
    1 context sentence
    Summary · context
    Nondiabetic women (n = 119; aged 18-45 years) with a body mass index (BMI) greater than 30 and less than 45 and polycystic ovary syndrome (National Institutes of Health criteria)

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In obese women with PCOS, exenatide plus dapagliflozin significantly improved mean glucose, insulin sensitivity and insulin secretion.

    In plain wordsIn obese women with PCOS, exenatide plus dapagliflozin improved mean blood sugar, insulin sensitivity and insulin secretion from baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedMean glucose, insulin sensitivity and secretion with combination
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Despite equivalent reductions in BMI and WC with PHEN/TPM, only EQW/DAPA and EQW resulted in significant improvements in MBG, SI, and IS.
    1 context sentence
    Summary · context
    Nondiabetic women (n = 119; aged 18-45 years) with a body mass index (BMI) greater than 30 and less than 45 and polycystic ovary syndrome (National Institutes of Health criteria)

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In obese women with PCOS, fasting glucose, testosterone, free androgen index and blood pressure decreased with all trial regimens, including exenatide.

    In plain wordsIn obese women with PCOS, glucose, testosterone, free androgen index and blood pressure fell with all regimens, including exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting glucose, testosterone, free androgen index and blood pressure
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight

    Source sentences

    Summary
    Reductions in fasting glucose, testosterone, FAI, and BP were seen with all drugs.
    1 context sentence
    Summary · context
    Nondiabetic women (n = 119; aged 18-45 years) with a body mass index (BMI) greater than 30 and less than 45 and polycystic ovary syndrome (National Institutes of Health criteria)

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02635386

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Woman'sn = 11922 Mar 2016 to 9 Oct 2020

Polycystic Ovary Syndrome · Obesity

Trial pageClinicalTrials.govUpdated 29 Jan 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.